NR-15260智人,单克隆抗人干扰素β蛋白,克隆A7(体外生产)(单克隆抗体）
产品图片
货号/SKU
NR-15260
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-15260??Homo sapiens, Monoclonal Anti-Human Interferon Beta Protein, Clone A7 (produced in vitro)(Monoclonal Antibodies)|Homo sapiens|Monoclonal Anti-Human Interferon Beta Protein, Clone A7 (produced in vitro)|-20°C or colder|SE GrossbergAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Human Interferon Beta Protein, Clone A7 (produced in vitro), NR-15260."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Antibody Class: IgG2aκ
Mouse monoclonal antibody prepared against a recombinant form of the human interferon beta (IFN-β) protein was purified from clone A7 hybridoma supernatant by protein G affinity chromatography. The B cell hybridoma was generated by the fusion of P3X63Ag8.653 myeloma cells with splenocytes from a BALB/c x DBA F1 mouse immunized repeatedly with recombinant human IFN-β protein in adjuvant. The clone A7 antibody is specific for human IFN-β and does not cross-react with IFN-α or IFN-γ.
NR-15260 recognizes recombinant human IFN-β in western blot assays. The clone A7 monoclonal antibody is also reported to function in ELISA, and to neutralize the anti-viral and anti-proliferative effects of unglycosylated recombinant IFN-β, but not of glycosylated natural IFN-β. The clone A7 antibody has been shown to recognize an epitope in the C1 helix of the IFN-β molecule, a site distant from the interferon α/β receptor subunit 2 (INFAR-2) binding residues.
Each vial of NR-15260 contains approximately 100 ?L of purified monoclonal antibody in PBS.
Antibody Class: IgG2aκ
Mouse monoclonal antibody prepared against a recombinant form of the human interferon beta (IFN-β) protein was purified from clone A7 hybridoma supernatant by protein G affinity chromatography. The B cell hybridoma was generated by the fusion of P3X63Ag8.653 myeloma cells with splenocytes from a BALB/c x DBA F1 mouse immunized repeatedly with recombinant human IFN-β protein in adjuvant. The clone A7 antibody is specific for human IFN-β and does not cross-react with IFN-α or IFN-γ.
NR-15260 recognizes recombinant human IFN-β in western blot assays. The clone A7 monoclonal antibody is also reported to function in ELISA, and to neutralize the anti-viral and anti-proliferative effects of unglycosylated recombinant IFN-β, but not of glycosylated natural IFN-β. The clone A7 antibody has been shown to recognize an epitope in the C1 helix of the IFN-β molecule, a site distant from the interferon α/β receptor subunit 2 (INFAR-2) binding residues.
Each vial of NR-15260 contains approximately 100 ?L of purified monoclonal antibody in PBS.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
抗体类：IgG2aκ
通过蛋白G亲和层析从克隆A7杂交瘤上清液纯化针对人干扰素β（IFN-β）蛋白的重组形式的小鼠单克隆抗体.通过P3X63AG8.653骨髓瘤细胞的熔化产生B细胞杂交瘤，其中来自BALB / C X DBA F1小鼠的脾细胞与佐剂重组人IFN-β蛋白重复免疫.克隆A7抗体是人IFN-β的特异性，并且不会与IFN-α或IFN-γ交叉反应.
NR-15260识别蛋白质印迹测定中的重组人IFN-β.克隆A7单克隆抗体也被报道在ELISA中起作用，并中和不糖基化重组IFN-β的抗病毒和抗增殖作用，但不是糖基化的天然IFN-β.已显示克隆A7抗体识别IFN-β分子的C1螺旋中的表位，来自干扰素α/β受体亚基2（infar-2）结合残留物的位点.
每个小瓶NR-15260在PBS中含有约100μl纯化的单克隆抗体.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2021-12-21
2024-01-21
2021-12-21
2022-04-01
2021-12-21
2020-06-09
2024-05-19
2020-08-04
2022-04-01
2022-04-01
2024-08-16
2022-04-01
2022-01-10
2021-12-21
2022-04-01
2022-04-01